Novel targets with potential therapeutic applications in osteosarcoma.
For patients with osteosarcoma, the development of metastases, often to the lungs, is the most common cause of death. Long-term outcomes for patients who present with localized or disseminated disease have largely remained unchanged over the past 20 years. Further improvements in outcome are not likely to come from intensification of cytotoxic chemotherapy; as such, new targets for treatment are needed. A view toward such targets in osteosarcoma may be constructed based on three common clinical features of the disease. These include the origin of osteosarcoma in the bone or primitive mesenchymal cells, the predictable process of metastatic progression characterized by this disease, and the development of metastatic lesions almost exclusively in the lung. It is likely and potentially favorable for some targets to be relevant for more than one process. This review summarizes novel targets under evaluation for the treatment of osteosarcoma based on these three features of the disease.
Khanna
Chand
C
National Institutes of Health, National Cancer Institute, Pediatric Oncology Branch, Tumor Metastasis Biology Section, 37 Convent Drive, Bethesda, MD 20892, USA. khannac@mail.nih.gov
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D006801:Humans; D020360:Neoadjuvant Therapy; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology*
D000970:Antineoplastic Agents
Life Sci. 2005 Mar 18;76(18):2091-101
15826876
Pediatr Blood Cancer. 2008 Jun;50(6):1190-7
18260118
Hematol Oncol Clin North Am. 2005 Jun;19(3):573-90, viii
15939198
Lancet. 2007 May 19;369(9574):1742-57
17512859
Clin Cancer Res. 2003 Nov 15;9(15):5442-53
14654523
Cancer. 2007 Mar 1;109(5):813-9
17265525
N Engl J Med. 1998 Aug 6;339(6):357-63
9691101
Curr Med Chem. 2007;14(20):2126-35
17691952
Expert Opin Investig Drugs. 2007 Sep;16(9):1459-65
17714031
Curr Med Chem. 2007;14(13):1381-7
17584050
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
14685170
J Clin Oncol. 2008 Feb 1;26(4):633-8
18235123
Expert Rev Anticancer Ther. 2006 Jul;6(7):1075-85
16831079
Nat Med. 2004 Feb;10(2):182-6
14704791
Clin Cancer Res. 2007 Nov 1;13(21):6247-51
17975134
Cancer Res. 2008 Mar 15;68(6):1935-44
18339875
J Clin Oncol. 1998 Nov;16(11):3641-8
9817286
Crit Rev Oncol Hematol. 2007 Dec;64(3):198-207
17855108
Curr Pharm Des. 2004;10(21):2577-92
15320746
Clin Cancer Res. 2002 Jul;8(7):2406-12
12114446
Nat Rev Drug Discov. 2007 Sep;6(9):734-45
17690708
Endocr Rev. 2007 Feb;28(1):20-47
16931767
Curr Pharm Biotechnol. 2008 Feb;9(1):2-8
18289051
Clin Cancer Res. 2006 Dec 15;12(24):7444-55
17189418
Histol Histopathol. 2004 Oct;19(4):1325-44
15375775
J Pediatr Surg. 2007 Jan;42(1):1-11
17208533
Curr Oncol Rep. 2007 Jul;9(4):316-22
17588357
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):211-7
17448875
Curr Opin Oncol. 2007 Jul;19(4):341-6
17545797
Pediatr Blood Cancer. 2008 Mar;50(3):581-7
17457854
J Cell Biochem. 2007 Dec 1;102(5):1095-102
17955492
Cancer Metastasis Rev. 2006 Dec;25(4):541-9
17180711
Cancer Res. 2004 Mar 15;64(6):2047-53
15026342
Cancer Res. 2007 Mar 15;67(6):2800-8
17363602
Med Hypotheses. 2008;70(2):281-6
17683874
Exp Cell Res. 2003 Nov 1;290(2):370-80
14567994
Biochem J. 2008 Mar 15;410(3):439-53
18290764
Nat Med. 2001 Jun;7(6):673-9
11385503
Science. 2004 Jul 9;305(5681):200-5
15247469
Int J Cancer. 2005 Jan 10;113(2):179-88
15455381
J Clin Oncol. 2005 Mar 20;23(9):2004-11
15774791
Cancer Res. 2005 Mar 15;65(6):2406-11
15781656
J Med Chem. 2007 Feb 22;50(4):603-6
17256836
Oncogene. 2008 Jan 24;27(5):684-93
17684486
Nat Rev Cancer. 2008 Feb;8(2):147-56
18202698
Cancer Cell Int. 2007 Sep 10;7:14
17845729
Clin Cancer Res. 2005 Jul 1;11(13):4666-73
16000559
Ann N Y Acad Sci. 2007 Oct;1113:202-16
17513464
Endocr Dev. 2005;9:11-16
15879684
Int J Oncol. 2006 Nov;29(5):1053-64
17016635
Clin Cancer Res. 2007 Mar 15;13(6):1625-9
17363512
Am J Pathol. 1996 Oct;149(4):1209-19
8863670
Genes Chromosomes Cancer. 2005 Feb;42(2):158-63
15540165
Eur J Cancer. 2004 Sep;40(14):2013-5
15341972
J Clin Invest. 2002 Jun;109(12):1607-15
12070308
Clin Exp Metastasis. 2003;20(5):421-30
14524531
Cancer Invest. 2007 Dec;25(8):785-94
18058475
Stem Cells Dev. 2007 Feb;16(1):7-23
17348802
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3263-70
18089720
Clin Exp Metastasis. 2008;25(3):201-11
18071913
Carcinogenesis. 2004 Dec;25(12):2293-301
15347599
Cancer Lett. 2005 Jul 8;225(1):1-26
15922853
Cancer Genet Cytogenet. 2007 Nov;179(1):52-61
17981215
Nature. 2005 Dec 15;438(7070):967-74
16355214
J Cell Physiol. 2007 Nov;213(2):316-25
17607709
Pediatr Blood Cancer. 2008 May;50(5):976-82
18213710
Eur J Cancer. 1997 Oct;33(11):1725-31
9470825
Clin Cancer Res. 2007 Dec 15;13(24):7243-6
18094402